ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO932

EXT-1/EXT-2 and NCAM-1 Expression in Taiwan Patients with Lupus Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Tu, Kun-Hua, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan
  • Wu, Tsai-yi, Chang Gung University, Taoyuan, Taoyuan, Taiwan
  • Tu, Yi-Ran, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan
Background

Lupus nephropathy could be divided into 6 categories according to WHO classification. Class V lupus nephropathy have similar histologic features with primary membranous nephropathy. There are several autoantibodies and autoantigens demonstrated in primary membranous nephropathy, since the discovery of anti-PLA2R. Similarly, there are also some novel autoantigens found in lupus membranous nephropathy. EXT-1/EXT-2 and NCAM-1 were postulated recently in lupus membranous nephropathy. Therefore, we conducted a prospective study to evaluate the prevalence of EXT-1/EXT-2 and NCAM-1 expression in patients with lupus membranous nephropathy.

Methods

This prospective invesitgation is conducted at a tertiary medical center in Taiwan. During the study period, there are totally 55 patients with pathologic diagnosis of lupus membranous nephropathy. In addition to routine histologic examination by experienced renal pathologist, the investigators completed the immunohistochesmistry (IHC) stain of PLA2R, EXT-1 and NCAM-1. Demographic datas and clinical informations were also collected and evaluated.

Results

Among the 55 subjects, there are 52 subjects with successful IHC stain for EXT-1 and 49 subjects with successful IHC stain for NCAM-1. All the subjects are negative of IHC stain for PLA2R. EXT-1 and NCAM-1 expression could be found with ratio of 26.9% (14/52) and 2.0% (1/49), respectively. Comparing with other group, the prevalence of EXT-1 and NCAM-1 in this investigation is relatively lower.

Conclusion

In this prospective investigation, we first demonstrate the prevalance of EXT-1 and NCAM-1 expression in Taiwan patients of lupus membranous nephropathy. The prevalence of these 2 autoantigen is lower than former studies. The role of these autoantigen is not clarified yet. Further studies are needed.